Exhibit 10.23
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SIGILON THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.
Consulting Agreement
[May Orfali, MD, MBA]
This Consulting Agreement (the “Agreement”), is made as of February 14, 2023 (the “Effective Date”) by and between Sigilon Therapeutics, Inc. (the “Company”), with offices at 100 Binney Street, Suite 600, Cambridge, MA 02142, and Rare Disease and Oncology Consulting, LLC/ May Orfali, MD, MBA (the “Consultant”).
In consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows:
[Signature page follows.]
IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.
SIGILON THERAPEUTICS, INC. | CONSULTANT |
| |
By:/s/ Rogerio Vivaldi | By: /s/ May Orfali |
Print Name: Rogerio Vivaldi | Print Name: May Orfali |
Title: President, CEO | Title: President |
Date: February 14, 2023 | Date: February 14, 2023 |
Note to Consultant
Please return a completed IRS Form W-9 to invoices@sigilon.com to enable payment.
Schedule A
Description of Services
The Consultant will provide services to the Company relating to the following:
[***]